RNA disruption caused by the angiogenesis inhibitor bevacizumab was explored using retrospective data from the NeoAva clinical trial, a neoadjuvant study of 132 eligible patients with early primary HER2- breast cancer. Here, ERBB2 is linked to breast carcinoma.